FLT3-ITD基因在急性髓细胞白血病患者中的突变及对预后影响分析

朱化超; 贺鹏程; 程小岩; 刘雁峰; 张梅

doi:10.13201/j.issn.1004-2806.2015.05.007

FLT3-ITD基因在急性髓细胞白血病患者中的突变及对预后影响分析

- 西安交通大学医学院第一附属医院血液内科(西安, 710061)
基金项目:
陕西省科技统筹创新工程计划项目(No:2012KTCL03-12)

详细信息

通讯作者: 张梅,E-mail:zhangmei@medmail.com.cn

中图分类号: R733.71

收稿日期: 2014-12-03

FLT3-ITD gene mutation and its prognostic significance in patients with acute myeloid leukemia

- Department of Hematology, The First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, 710061, China

More Information

Corresponding author: ZHANG Mei, E-mail: zhangmei@medmail.com.cn

Received Date: 03 December 2014

摘要

摘要: 目的:分析急性髓细胞白血病(AML)患者中fms样酪氨酸激酶3(FLT3)基因的内部串联重复(internal tandem duplication,ITD)突变的发生率,以及该突变对患者的血常规水平、免疫表型、完全缓解(CR)率和总生存时间的影响。探讨FLT3 ITD(+)AML患者服用索拉菲尼对中位生存时间的影响。方法:采用PCR方法检测130例初诊急性髓细胞白血病患者骨髓中FLT3-ITD的表达,用Kaplan-Meier生存曲线分析AML的预后。结果:130例初发AML患者中检出FLT3-ITD(+)患者共23例(17.7%)。FLT3-ITD(+)患者发病时白细胞高、骨髓原始细胞比例高(P<0.05),FLT3-ITD(+)对AML(除外APL)患者的CR率、OS时间均有不良影响(P<0.05)。索拉菲尼联合化疗的FLT3-ITD(+)患者的中位生存时间有所延长(12个月,未口服则为7个月)。结论:FLT3-ITD突变是AML患者中常见的基因突变类型,FLT3-ITD(+)降低患者的CR率,缩短OS。索拉菲尼可作为FLT3-ITD(+)急性髓细胞白血病患者的治疗选择。
- 急性髓细胞白血病 /
- FL3-ITD /
- 基因突变 /
- 索拉菲尼
Abstract: Objective:To analyze the prevalence of internal tandem duplication mutations in the FMS like tyrosine 3 (FLT3 ITD) in acute myeloid leukemia,and the mutation's influence on the blood cell counts,immunophenotype,complete remission (CR) rate and overall survival(OS) time.To investigate the median survival time of FLT3 ITD (+) patients with sorafenib.Method:The mutation of FLT3 ITD in bone sameples from 130 patients with de novo AML were screened by polymerase chain reaction(PCR),analyze the prognosis of AML by Kaplan-Meier survival curve.Result:FLT3-ITD(+) were found in 23(17.7%) of 130 de novo AML patients,and was associated with higher white cell count(P<0.05) and higher percentage of bone marrow blast cells(P<0.05).FLT3-ITD(+)have lower CR rate and OS time than the negative.The median survival time is lengthened from 7 months to 12 months for the FLT3-ITD(+) patients taking sorafenib.Conclusion:FLT3-ITD mutations is a common genetic abnormality in AML patients and associated with low CR rate and short overall survival.Sorafenib show activity in FLT-ITD(+) AML patients.
- acute myeloid leukemia /
- FLT3-ITD /
- gene mutation /
- sorafenib

HTML全文

参考文献(12)

[1]	McCormick SR,McCormick MJ,Grutkoski PS,et al.FLT3 mutations at diagnosis and relapse in acute myeloid leukemia:cytogenetic and pathologic correlations,including cuplike blast morphology[J].Arch Pathol Lab Med,2010,134:1143-1151.
[2]	Fathi AT,Chabner BA.FLT3 inhibition as therapy in acute myeloid leukemia:a record of trials and tribulations[J].Oncologist,2011,16:1162-1174.
[3]	Song G,Valdez BC,Li Y,Liu Y,Champlin RE,Andersson BS.Synergistic Cytotoxicity of Sorafenib with Busulfan and Nucleoside Analogs in Human FMS-like Tyrosine Kinase 3 Internal Tandem Duplications-Positive Acute Myeloid Leukemia Cells[J].Biol Blood Marrow Transplant,2014,20:1687-1695.
[4]	Sharawat SK,Bakhshi R,Vishnubhatla S,Gupta R,Bakhshi S.FLT3-ITD mutation in relation to FLT3 expression in pediatric AML:a prospective study from India[J].Pediatr Hematol Oncol,2014,31:131-137.
[5]	丁子轩,沈宏杰,吴德沛,等.C-kit、NPM1、FLT3基因突变在656例中国急性髓系白血病患者中的分布及其对预后的影响[J].中华血液学杂志,2012,33(10):829-834.
[6]	Su L,Gao SJ,Li W,et al.NPM1,FLT3-ITD,CEBPA,and c-kit mutations in 312 Chinese patients with de novo acute myeloid leukemia[J].Hematology,2014,19:324-328.
[7]	Poire X,Moser BK,Gallagher RE,et al.Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710):prognostic significance of FLT3 mutations and complex karyotype[J].Leuk Lymphoma,2014,55:1523-1532.
[8]	Man CH,Fung TK,Ho C,et al.Sorafenib treatment of FLT3-ITD (+) acute myeloid leukemia:favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation[J].Blood,2012,119:5133-5143.
[9]	Sammons SL,Pratz KW,Smith BD,et al.Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant[J].Am J Hematol,2014,89:936-938.
[10]	Baker SD,Zimmerman EI,Wang YD,et al.Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia[J].Clinical Cancer Research,2013,19:5758-5768.
[11]	Borthakur G,Kantarjian H,Ravandi F,et al.Phase I study of sorafenib in patients with refractory or relapsed acute leukemias[J].Haematologica,2011,96:62-68.
[12]	Sharma M,Ravandi F,Bayraktar UD,et al.Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib[J].Biol Blood Marrow Transplant,2011,17:1874-1877.